Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTC’s)

Table 2 Treatment response and duration

Patient	First treatment	Surgery resection quality	Radiotherapy	PFS 1	Relapses treatments/PFS	Lines of treatment before TT	TT type	PFS with TT (months)
1	MAID^a-ASCT^b	R2	_	12 months	Gemcitabine-cisplatine/2,5 months	2	Sunitinib	2
2	LV5Fu-Ciplatine	_	_	8 months	HIPEC^c-FOLFIRI^d/17 months FOLFIRI/3 months Holoxan-etoposide/3 months Adriamycine-cyclophosphamide/2 months	5	Sorafenib	3.5
3	MAI^e	R1	Yes	39 months	Gemcitabine-docetaxel/4 months Adriamycine-holoxan/3 months Cisplatine-irinotecan/6 months Trabectedine/9 months	5	Sorafenib	4
4	Adriamycine-etposide-Cisplatine-Cyclophosphamide + VAI^f	R2	_	44 months	Carboplatine-etoposide/13 months	2	Sunitinib	5.5
5	Cyclophosphamide-etoposide-carboplatine	R1	Yes	47 months	Etoposide-carboplatine-busulfan-thiotepa/12 months Temozolamide/5 months TEMIRI^g/4 months	4	Bevacizumab	2
6	MAI	_	_	6 months	VAC^h/6 months	2	Ridaforolimus PFS 23 months Sunitinib	4 OS 38 months
7^j	Bevacizumab-IVADoⁱ	R1	Yes	7 months	Navelbine-cyclophosphamide/10 months	2	Dalotuzumab PFS 2 months Sunitinib	3
8	Adriamycine-ifosfamide-etoposide	_	_	6 months	Cyclophosphamide/3 months Trabectedine/4 months	3	Sunitinib	2 OS 19 months
9	MAI	_	_	7 months	VAC/3 months	2	Sunitinib	2

^aMesna-Adriblastine-Ifosfamide-Dacarbazine
^bAutologous stem cell transplantation
^cHyperthermic intraperitoneal chemotherapy
^d5 Fluorouracile-Oxaliplatine-Irinotecan
^eMesna-Adriblastine-Ifosfamide
^fVincristine-Actinomycine D-Ifosfamide
^gTemozolamide-Irinotecan
^hVincristine-Actinomycine D-Cyclophosphamide
ⁱIfosfamide-Vincristine-Actinomycine D-Doxorubicine
^jThis patient had TT bevacizumab in first line treatment as part of BERNIE study in combination with IVADo polychemotherapy. The second relapse was treated with dalotuzumab, he received temodal-irinotecan for third relapse (PFS 8 months) and he finally had sunitinib for the fourth relapse

ISSN: 2045-3329